tiprankstipranks
Advertisement
Advertisement

VSTM Stock Latest News

Verastem doses first patient in TARGET-D 202 Phase 2 trial
The FlyVerastem doses first patient in TARGET-D 202 Phase 2 trial
4h ago
VSTM
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer
PremiumCompany Announcements
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer
5d ago
VSTM
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens healthcare analysts hold an analyst/industry conference call
15d ago
CTMX
EXEL
Verastem price target lowered to $14 from $15 at RBC Capital
PremiumThe Fly
Verastem price target lowered to $14 from $15 at RBC Capital
16d ago
VSTM
Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer
PremiumCompany Announcements
Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer
20d ago
VSTM
Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock
PremiumWeekend UpdatesCardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock
25d ago
QSI
CRDF
Verastem Advances VS-7375 with Promising Early Trial Data
Premium
Company Announcements
Verastem Advances VS-7375 with Promising Early Trial Data
29d ago
8K
VSTM
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
Premium
The Fly
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
29d ago
VSTM
Verastem price target lowered to $8 from $15 at Jefferies
PremiumThe Fly
Verastem price target lowered to $8 from $15 at Jefferies
29d ago
VSTM
Verastem’s KRAS G12D Pancreatic Cancer Trial Advances: What Investors Should Watch
PremiumCompany Announcements
Verastem’s KRAS G12D Pancreatic Cancer Trial Advances: What Investors Should Watch
29d ago
VSTM
Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
PremiumCompany Announcements
Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
1M ago
8K
VSTM
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
PremiumThe Fly
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
1M ago
VSTM
Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375
PremiumThe FlyVerastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375
1M ago
VSTM
3 Best Stocks to Buy Today, According to Top Analysts, 6/9/2026
Premium
Market News
3 Best Stocks to Buy Today, According to Top Analysts, 6/9/2026
1M ago
EVLV
SPTX
Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375
Premium
The Fly
Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375
2M ago
VSTM
Verastem announces FDA Fast Track designation for VS-7375
PremiumThe Fly
Verastem announces FDA Fast Track designation for VS-7375
2M ago
VSTM
Verastem Shareholders Back Board, Executive Pay and Plans
PremiumCompany Announcements
Verastem Shareholders Back Board, Executive Pay and Plans
2M ago
8K
VSTM
Verastem appoints Michael Bailey to board of directors
PremiumThe Fly
Verastem appoints Michael Bailey to board of directors
2M ago
VSTM
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts
PremiumMarket News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts
2M ago
WVE
REAX
Verastem price target lowered to $14 from $16 at Mizuho
PremiumThe FlyVerastem price target lowered to $14 from $16 at Mizuho
2M ago
VSTM
Verastem Inc Earnings Call Highlights Growth And Risk
Premium
Company Announcements
Verastem Inc Earnings Call Highlights Growth And Risk
2M ago
VSTM
Verastem price target lowered to $18 from $19 at BTIG
Premium
The Fly
Verastem price target lowered to $18 from $19 at BTIG
3M ago
VSTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >